Bayer to cut 12,000 jobs worldwide as company faces 10,000 lawsuits over Monsanto’s Roundup (glyphosate) herbicide causing cancer
by: Ethan Huff
NaturalNews.com
Sunday, December 02, 2018
German chemical giant Bayer has become the new Monsanto, having acquired the world’s most evil corporation earlier this year for $62.5 billion. But with this acquisition has come a litany of pending lawsuits so costly that Bayer is now having to fire some 12,000 of its employees worldwide.
As originally reported by the Financial Times, Bayer is shedding this massive number of employees in a desperate attempt to “regain investor confidence” in the company now that it’s become Monsanto on steroids.
In addition to firing 12,000 employees, Bayer is also cutting ties with its animal health products division, as well as two other divisions it owns: Coppertone sun care and Dr. Scholl’s foot care products. Bayer is also planning to sell its 60 percent stake in Currenta, a service provider of utilities, environmental services, safety and security, analytics, and training.
The shot heard ’round the world was a recent decision by San Francisco Superior Court Judge Suzanna Bolanos who reportedly sided with jurors in a case involving a man who developed non-Hodgkin’s lymphoma from being exposed to glyphosate, the primary active ingredient in Monsanto’s Roundup herbicide.
This ruling by Judge Bolanos gave precedent to the tens of thousands of other pending lawsuits against Monsanto that will now fall on Bayer as they move through the courts. By acquiring Monsanto, in other words, Bayer is also acquiring a very long list of pending litigation against Monsanto that has yet to see justice.
Bayer denies that drastic changes have anything to do with Monsanto litigation
Even as Bayer frantically shuffles around its business model in a desperate attempt to thwart the impact of these many pending lawsuits, the company insists that none of this has anything to do with the lawsuits.
“These measures are totally unrelated,” Bayer chief executive officer (CEO), Werner Baumann, told the Financial Times during a recent conference call.
“They don’t have anything to do with the acquisition of Monsanto and the glyphosate litigation … These measures stand on their own and they are aimed at further improving the competitiveness of the company going forward.”
According to Baumann, all of these planned measures will help to “free up resources for innovation and growth,” allowing the multinational corporation to better focus “on our core businesses in pharmaceuticals, consumer health and crop science.”
Will tens of thousands of lawsuit against Monsanto/Bayer bankrupt this entity of evil?
The Rest…HERE
